Adaptin Bio, Inc., a Lucius Partners Portfolio Company, Completes Alternative Public Offering (APO) and Closes $7.7 Million Private Placement
Funding expected to support first clinical trial of APTN-101 for the treatment of glioblastoma CHARLOTTE, N.C., April 07, 2025 (GLOBE NEWSWIRE) ...